Background: In a prospective, single-center open study, we evaluated the very long-term effects of rituximab (RTX) administered to patients with severe mixed cryoglobulinemia (MC). Methods: RTX was administered to 31 patients with MC (type II in 29 cases and type III in 2) with diffuse membranoproliferative glomerulonephritis (16 cases), peripheral neuropathy (26) and large skin ulcers (7). All but 4 patients had serum anti-hepatitis C virus antibodies. RTX was administered at a dose of 375 mg/m2, according to a ‘4 + 2' protocol (days 1, 8, 15 and 22 plus 1 dose 1 and 2 months later). No other immunosuppressive drugs were added. Response was evaluated over a very long-term follow-up (mean 72.47 months, range 30-148). Results: Complete remission of pretreatment active manifestations was observed in all cases of purpuric lesions and non-healing vasculitic ulcers, and in 80% of the peripheral neuropathies. Cryoglobulinemic nephropathy significantly improved during follow-up, starting from the 2nd month after RTX (serum creatinine from 2.1 ± 1.7 to 1.5 ± 1.6 mg/dl, p ≤ 0.05; 24-hour proteinuria from 2.3 ± 2.1 to 0.9 ± 1.9 g/24 h, p ≤ 0.05). Improvement of cryoglobulinemic serological hallmarks, such as cryocrit and low complement C4, were observed. No clinically relevant side effects were recorded. Re-induction with RTX was carried out in 9 relapsed patients after a mean of 31.1 months (12-54), again with beneficial effects. The survival rate was 75% at 6 years and the probability of remaining symptom-free for 10 years without any therapy was of about 60% after a single ‘4 + 2' infusion cycle, while the probability of living symptom-free 5 years after relapsing was 80% if given the same treatment. Conclusion: In this open, prospective study, RTX appeared to be very effective and safe in the treatment of the most severe cases of MC.

Keywords:
Mixed cryoglobulinemia, Vasculitis, Membranoproliferative glomerulonephritis, Polyneuritis, Necrotizing skin ulcers, Rituximab, Anti-CD20 monoclonal antibodies, B cell depletion
1.
Ramos-Casals M, Stone JH, Cid MC, Bosch X: The cryoglobulinaemias. Lancet 2012;379:348-360.
2.
Monti G, Saccardo F, Castelnovo L, Novati P, Sollima S, Riva A, et al: Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. Autoimmun Rev 2014;13:609-614.
3.
Belizna C, Loufrani L, Subra JF, Godin M, Jolly P, Vitecocq O, et al: A 5-year prospective follow-up study in essential cryofibrinogenemia patients. Autoimmun Rev 2011;10:559-562.
4.
Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, et al: B-cells and mixed cryoglobulinemia. Autoimmun Rev 2007;7:114-120.
5.
Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, et al: Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054-3061.
6.
Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, et al: Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011;10:444-454.
7.
Kattah AG, Fervenza FC, Roccatello D: Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev 2013;12:854-859.
8.
Roccatello D, Baldovino S, Rossi D, Giachino O, Mansouri M, Naretto C, et al: Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008;34:111-117.
9.
Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, et al: Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011;11:48-55.
10.
Damoiseaux J: The diagnosis and classification of the cryoglobulinemic syndrome. Autoimmun Rev 2014;13:359-362.
11.
Terrier B, Marie I, Launay D, Lacraz A, Belenotti P, de Saint-Martin L, et al: Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey. Autoimmun Rev 2014;13:630-634.
12.
Terrier B, Chaara W, Dufat L, Geri G, Rosenzwajg M, Musset L, et al: Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection. Autoimmun Rev 2014;13:319-326.
13.
Visentini M, Conti V, Cristofoletti C, Lazzeri C, Marrapodi R, Russo G, et al: Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: the yin and yang of HCV-driven lymphoproliferation and autoimmunity. Autoimmun Rev 2013;12:430-435.
14.
Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, et al: A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment - clinical response compared to literature and immunological re-assessment. Autoimmun Rev 2015;14:1123-1130.
15.
Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C: Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev 2015;14:1072-1078.
16.
Giuggioli D, Manfredi A, Colaci M, Manzini CU, Antonelli A, Ferri C: Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev 2013;12:1058-1063.
17.
Dumoitier N, Terrier B, London J, Lofek S, Mouthon L: Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev 2015;14:996-1004.
18.
Roccatello D, Fornasieri A, Giachino O, Rossi D, Beltrame A, Banfi G, et al: Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007;49:69-82.
19.
Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-3826.
20.
Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, et al: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-3834.
21.
De Vita S, Quartuccio L, Fabris M: Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig Liver Dis 2007;39(suppl 1):S122-S128.
22.
Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P: Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008;111:5334-5341.
23.
Sène D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P: Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009;60:3848-3855.
24.
Cavallo R, Roccatello D, Menegatti E, Naretto C, Napoli F, Baldovino S: Rituximab in cryoglobulinemic peripheral neuropathy. J Neurol 2009;256:1076-1082.
25.
Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, et al: Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116:326-334.
26.
Terrier B, Saadoun D, Sène D, Sellam J, Pérard L, Coppéré B, et al: Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 2009;60:2531-2540.
27.
Terrier B, Launay D, Kaplanski G, Hot a, Larroche C, Cathébras P, et al: Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French autoimmunity and rituximab registry. Arthritis Care Res (Hoboken) 2010;62:1787-1795.
28.
Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, et al: Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010;116:335-342.
29.
Gragnani L, Piluso A, Giannini C, Caini P, Fognani E, Monti M, et al: Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors. Arthritis Rheum 2011;63:1446-1451.
30.
Visentini M, Ludovisi S, Petrarca A, Pulvirenti F, Zaramella M, Monti M, et al: A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011;10:714-719.
31.
Stasi C, Triboli E, Arena U, Urraro T, Petrarca A, Gragnani L, et al: Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. J Transl Med 2014;12:21.
32.
Visentini M, Tinelli C, Colantuono S, Monti M, Ludovisi S, Gragnani L, et al: Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun Rev 2015;14:889-896.
33.
Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, et al: Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010;116:343-353.
34.
Sneller MC, Hu Z, Langford CA: A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:835-842.
35.
De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, et al: A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:843-853.
36.
Elbaz T, El-Kassas M, Esmat G: New era for management of chronic hepatitis C virus using direct antiviral agents: a review. J Adv Res 2015;6:301-310.
37.
Saadoun D, Delluc A, Piette JC, Cacoub P: Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008;20:23-28.
38.
Saadoun D, Resche-Rigon M, Sene D, Perard L, Karras a, Cacoub P: Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 2008;67:1431-1436.
39.
Sansonno D, Tucci FA, Montrone M, Troiani L, Sansonno L, Gatti P, et al: B-cell depletion in the treatment of mixed cryoglobulinemia. Dig Liver Dis 2007;39(suppl 1):S116-S121.
40.
De Vita S, Quartuccio L, Fabris M: Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both? Autoimmun Rev 2008;8:95-99.
41.
Visentini M, Granata M, Veneziano ML, Borghese F, Carlesimo M, Pimpinelli F, et al: Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 2007;125:30-33.
42.
Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, et al: Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067-2077.
43.
Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, et al: Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 2016;63:408-417.
44.
Saadoun D, Resche Rigon M, Pol S, Thibault V, Blanc F, Pialoux G, et al: PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 2015;62:24-30.
45.
Saadoun D, Thibault V, Pialoux G, Elkrief L, Mallet M, Musset L, et al: P0813: all oral therapy (Sofosbuvir-Ribavirin) combination in severe HCV-mixed cryoglobulinemia vasculitis, the vascuvaldic study. J Hepatol 2015;62(suppl 2):S640.
46.
Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A, et al: Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618-623.
47.
Terrier B, Semoun O, Saadoun D, Sène D, Resche-Rigon M, Cacoub P: Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum 2011;63:1748-1757.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.